C12N 2710/20011
Papillomaviridae
C12N2710/20011 (Papillomaviridae) appears on 840 US grants and 1,228 published applications in this corpus.
Search patents in C12N- Granted patents
- 840
- Published applications
- 1,228
- Assignees
- 581
- Inventors
- 2,066
- Latest grant
- 22 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1983 | 1 | 0 |
| 1984 | 0 | 0 |
| 1985 | 1 | 0 |
| 1986 | 1 | 0 |
| 1987 | 0 | 0 |
| 1988 | 1 | 0 |
| 1989 | 2 | 0 |
| 1990 | 0 | 0 |
| 1991 | 2 | 0 |
| 1992 | 2 | 0 |
| 1993 | 3 | 0 |
| 1994 | 2 | 0 |
| 1995 | 8 | 0 |
| 1996 | 5 | 0 |
| 1997 | 27 | 0 |
| 1998 | 26 | 0 |
| 1999 | 26 | 0 |
| 2000 | 19 | 0 |
| 2001 | 26 | 9 |
| 2002 | 29 | 25 |
| 2003 | 23 | 39 |
| 2004 | 18 | 55 |
| 2005 | 18 | 49 |
| 2006 | 16 | 42 |
| 2007 | 33 | 41 |
| 2008 | 30 | 39 |
| 2009 | 23 | 38 |
| 2010 | 25 | 57 |
| 2011 | 15 | 36 |
| 2012 | 23 | 41 |
| 2013 | 14 | 28 |
| 2014 | 28 | 36 |
| 2015 | 29 | 46 |
| 2016 | 28 | 45 |
| 2017 | 41 | 46 |
| 2018 | 38 | 54 |
| 2019 | 28 | 58 |
| 2020 | 33 | 46 |
| 2021 | 37 | 74 |
| 2022 | 42 | 56 |
| 2023 | 35 | 83 |
| 2024 | 30 | 81 |
| 2025 | 37 | 73 |
| 2026 | 15 | 31 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- C12N 2710/20022New viral proteins or individual genes, new structural or functional aspects ofIndexing code519
- C12N 2710/20034Use of virus or viral component as vaccineIndexing code475
- C12N 2710/20023Virus like particles [vlp]Indexing code170
- C12N 2710/20071Demonstrated in vivo effectIndexing code58
- C12N 2710/20041Use of virus, viral particle or viral elements as a vectorIndexing code31
- C12N 2710/20051Methods of production or purification of viral materialIndexing code24
- C12N 2710/20033Use of viral protein as therapeutic agent other than vaccineIndexing code17
- C12N 2710/20032Use of virus as therapeutic agent, other than vaccineIndexing code13
Recent patents
- Engineered DNA molecule for coding RNA22 Sep 2026US 12,742,172 B2Rinuagene Biotechnology Co., Ltd.
- Sequential heterologous boost oncolytic viral immunotherapy25 Aug 2026US 12,714,733 B2Children's Hospital of Eastern Ontario Research Institute Inc.
- Methods of preparing anti-human papillomavirus antigen T cells11 Aug 2026US 12,702,706 B2The United States of America, as represented by the Secretary, Department of Health and Human Seervices
- Cell capable of activating immune system, and pharmaceutical composition containing said cell11 Aug 2026US 12,703,867 B2Riken
- Thermostable lipid nanoparticle and methods of use thereof4 Aug 2026US 12,697,308 B2Merck Sharp & Dohme Corp.
- A novel non-stoichiometric multi-element adjuvant (nsma) and composition thereof8 Oct 2026US 2026/0306624 A1Magvitae Innovations Inc
- Compositions and methods for peptide-based modulators of human papillomavirus oncoprotein e61 Oct 2026US 2026/0297131 A1Calico Life Sciences LLC
- Methods and compositions comprising cationic lipids for stimulating type 1 interferon genes27 Aug 2026US 2026/0248753 A1PDS Biotechnology Corporation
- A Fusion Protein and a Particulate Antigen Containing the Same27 Aug 2026US 2026/0250328 A1Xiamen Innovax Biotech Co., Ltd.
- A therapeutic hpv vaccine based on validated target epitopes20 Aug 2026US 2026/0240974 A1Deutsches Krebsforschungszentrum Stiftung des Offentlichen Rechts
Most cited
By later US patents
- Recombinant DNA process utilizing a papilloma virus DNA as a vector284US 4,419,446 AThe United States of America as represented by the Department of Health and Human Services · 1983
- Mammalian metallothionein promoter system224US 4,601,978 AThe Regents of the University of California · 1986
- Amplification of nucleic acid molecules198US 5,169,766 ALife Technologies Corporation · 1992
- Antisense oligonucleotide inhibition of papillomavirus194US 5,457,189 AIsis Pharmaceuticals, Inc. · 1995
- Fusion protein comprising tat-derived transport moiety177US 5,674,980 A1997